Nivolumab plus Ipilimumab has shown continued survival benefit at 42-month follow-up in patients with previously untreated advanced or metastatic renal cell carcinoma
Updated results from the phase 3 CheckMate -214 study evaluating the combination of Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) versus Sunitinib( Sutent ) in patients with previously untreated adv ...
read article